Comparison

Xlung App vs ASSOBRAFIR

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

Xlung App

This app provides a comprehensive set of tools for mechanical ventilation management. It includes over 15 calculators, practical tips, and patient monitoring features designed for intensive care professionals and students.

Highlights
  • Mechanical ventilation calculators
  • Ventilatory support tips
  • Patient registration and monitoring
  • Bedside fundamentals
  • Systematic checklist for assistance
Features
Read full description

Education and quick reference for safer, more precise mechanical ventilation, when it matters most. The Xlung App puts the essential formulas, calculations, and clinical pearls of ventilatory support in the palm of your hand — so you can apply your knowledge quickly and safely where it matters most. From invasive mechanical ventilation to noninvasive ventilation (NIV), from helmet interfaces to high-flow nasal cannula (HFNC): the essentials of respiratory support in one place. Built for physicians, respiratory therapists, physical therapists, nurses, residents, students, and other healthcare professionals working in critical care, emergency medicine, and respiratory care. What you'll find in the Xlung App: - Essential formulas for daily practice — the must-have calculations of mechanical ventilatory support, with interpretation tips for out-of-range values and bibliographic references for each one. - Continuously updated ventilatory support tips — curated by the Xlung platform's expert consulting team and grounded in the best and most current scientific evidence. - SI and US units — switch between mmHg and kPa to match your practice. - Expert-curated notifications — stay on top of what's new on the Xlung platform and in the world of respiratory support. Built by professionals who have practiced and taught for decades. The Xlung App draws on the 25+ years of experience of Marcelo Alcantara Holanda, MD, Ph.D., pulmonologist, intensivist, and founder of the Xlung platform — an international reference in simulation-based mechanical ventilation education — with special consulting by Betina Santos Tomaz, PT, Ph.D., a physical therapist specializing in critical care and respiratory care, with extensive clinical and teaching experience in Brazil and abroad. Together with the platform's team of consultants and developers, they make the Xlung App a one-of-a-kind tool worldwide. Start for free. Download the app and access a set of formulas and features at no cost. A single in-app purchase unlocks all tools, all content, and all future features. Enjoying the Xlung App? Take a minute to leave us a rating—it truly helps us bring safer respiratory support to more professionals worldwide. Important: The Xlung App is an educational and quick-reference tool. It does not make diagnoses or clinical decisions. All decisions regarding patient care are the sole responsibility of a duly licensed healthcare professional, based on their clinical judgment, the assessment of each patient, and their institution's guidelines and protocols. Terms of Use (EULA): https://app-xlung-privacy.xlung.org/en/terms Privacy Policy: https://app-xlung-privacy.xlung.org/en/privacy

About

ASSOBRAFIR

This app provides members of the Brazilian Association of Cardiorespiratory Physiotherapy and Intensive Care Physiotherapy with news, push notifications, and association status updates. It offers a fully online and digital experience for members.

Highlights
  • News updates
  • Push notifications
  • Association status check
  • Digital member benefits
  • Online platform
Features
Read full description

O App da ASSOBRAFIR é mais um benefício para os associados. Acompanhe nossas notícias, notificações via push, confira o status da sua associação e muito mais! A Associação Brasileira de Fisioterapia Cardiorrespiratória e Fisioterapia em Terapia Intensiva agora em versão totalmente on-line e 100% digital.

Screenshots

Xlung App4 screens
ASSOBRAFIR3 screens

Verdict

The call

The clearest difference is review sentiment: Xlung App at 67% against ASSOBRAFIR's 0%. ASSOBRAFIR's advantage is in-app purchases (none vs 1). On price, update cadence, ads and device support there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. Xlung App sells 1 in-app purchase, starting at $5.49 per month. ASSOBRAFIR asks for nothing beyond the download.

UpkeepUpdate frequency

Xlung App ships an update every 2 months, ASSOBRAFIR every 3 months. The most recent releases landed on October 24, 2026 and October 22, 2026 respectively.

Scorecard3 real differences · 5 level
Xlung App versus ASSOBRAFIR: the parameters behind the verdict, then further details
ParameterXlung AppASSOBRAFIR
PriceFreeFree
Positive reviews66.7% of reviews — better0.0% of reviews
Update frequencyEvery 2 months — betterEvery 3 months
AdsNoNo
In-app purchasesYesNo — better
MonetizationSubscriptionFree — better
DevicesiPhone, iPadiPhone, iPad, iPod — better
Requires iOS16.415.1 — better
Further details — not scored
Size45 MB68 MB
Age rating17+4+
DeveloperXlung Educação em SaúdeItarget Tecnologia

Customer experience

Xlung App

Written reviews3 reviews
Positive66.7%
Neutral0.0%
Negative33.3%

ASSOBRAFIR

Written reviews1 reviews
Positive0.0%
Neutral100.0%
Negative0.0%

In-app purchases

1 purchases

Xlung App

Subscriptions1
  • Monthly Plan$5.491 Month
None

ASSOBRAFIR

No in-app purchases

Questions

Is Xlung App free?
Xlung App is free to download, with in-app purchases available.
Is ASSOBRAFIR free?
ASSOBRAFIR is free to download, with no in-app purchases.
Do Xlung App or ASSOBRAFIR have ads?
Neither Xlung App nor ASSOBRAFIR shows ads.
Which is updated more often, Xlung App or ASSOBRAFIR?
Xlung App ships an update every 2 months, and ASSOBRAFIR every 3 months. Most recently, Xlung App was updated on October 24, 2026 and ASSOBRAFIR on October 22, 2026.

Other comparisons